WHO: Prequalification could enhance malaria treatment

The World Health Organization has prequalified a novel diagnostic test to detect glucose-6-phosphate dehydrogenase deficiency.

There are about 500,000 deaths from malaria per year, the agency detailed in a news report. The novel G6PD deficiency test — which is capable of measuring the G6PD enzyme activity in capillary or venous whole blood — was designed to help streamline safe and effective treatments and protect against relapse from the malaria parasite Plasmodium vivax by identifying patients at risk of hemolysis following antirelapse treatment. The decision demonstrated the WHO’s commitment to improving access to malaria treatments in low- and lower-middle-income countries and achieving global health equity.

The WHO hopes the G6PD deficiency test can ultimately help reduce the burden of P. vivax infections across the world.

Read more: WHO

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.